RxSight (RXST) Cash from Financing Activities (2020 - 2026)

RxSight (RXST) has reported Cash from Financing Activities for 7 consecutive years, with $662000.0 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Cash from Financing Activities fell 67.94% year-over-year to $662000.0; the trailing twelve-month figure through Jun 2026 stood at $859000.0 (down 83.43% YoY), and the FY2025 full-year result was $1.9 million, down 98.49% from the prior year.
• Cash from Financing Activities improved to $662000.0 in Q2 2026 per RXST's latest filing, from -$336000.0 in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $111.5 million in Q2 2024 and bottomed at -$8.2 million in Q3 2023.
• Historically, Cash from Financing Activities has averaged $10.7 million across 5 years, with a median of $884500.0 in 2023.
• The widest YoY moves for Cash from Financing Activities: up 66737.76% in 2023, down 1709.67% in 2023.
• Over 5 years, Cash from Financing Activities stood at $6.3 million in 2022, then sank by 43.52% to $3.6 million in 2023, then declined by 16.45% to $3.0 million in 2024, then tumbled by 64.28% to $1.1 million in 2025, then sank by 37.72% to $662000.0 in 2026.
• According to Business Quant data, Cash from Financing Activities over the past three periods registered $662000.0, -$336000.0, and $1.1 million for Q2 2026, Q1 2026, and Q4 2025 respectively.